Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study

W. F. Spencer, W. M. Linehan, M. M. Walther, G. P. Haas, M. T. Lotze, Suzanne Topalian, J. C. Yang, M. J. Merino, Julie R Lange, B. A. Pockaj, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

A total of 12 patients with stage 4 renal cell carcinoma and primary renal tumors in situ was entered into a pilot study using treatment with interleukin-2 and α-interferon followed by radical nephrectomy. Of the patients 11 underwent nephrectomy after an initial course of immunotherapy. Ten patients were able to receive a second course of immunotherapy given after nephrectomy. One patient achieved a complete response of lung and mediastinal metastases without any change in the primary renal tumor but after nephrectomy the patient remained in complete remission for greater than 11 months. A total of 3 patients achieved a partial response at some extrarenal sites but they had progression elsewhere. Toxicity was similar to previous experience with this immunotherapy regimen. Therefore, we demonstrated that metastatic tumor regression is possible with primary renal tumors in situ and that aggressive interleukin-2-based immunotherapy can be tolerated in the presence of a large renal tumor.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalJournal of Urology
Volume147
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interferons
Interleukin-2
Nephrectomy
Kidney
Neoplasms
Neoplasm Metastasis
Lung

Keywords

  • carcinoma, renal cell
  • immunotherapy
  • interferon type I
  • interleukin-2
  • kidney neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Spencer, W. F., Linehan, W. M., Walther, M. M., Haas, G. P., Lotze, M. T., Topalian, S., ... Rosenberg, S. A. (1992). Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study. Journal of Urology, 147(1), 24-30.

Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers : A pilot study. / Spencer, W. F.; Linehan, W. M.; Walther, M. M.; Haas, G. P.; Lotze, M. T.; Topalian, Suzanne; Yang, J. C.; Merino, M. J.; Lange, Julie R; Pockaj, B. A.; Rosenberg, S. A.

In: Journal of Urology, Vol. 147, No. 1, 1992, p. 24-30.

Research output: Contribution to journalArticle

Spencer, WF, Linehan, WM, Walther, MM, Haas, GP, Lotze, MT, Topalian, S, Yang, JC, Merino, MJ, Lange, JR, Pockaj, BA & Rosenberg, SA 1992, 'Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study', Journal of Urology, vol. 147, no. 1, pp. 24-30.
Spencer, W. F. ; Linehan, W. M. ; Walther, M. M. ; Haas, G. P. ; Lotze, M. T. ; Topalian, Suzanne ; Yang, J. C. ; Merino, M. J. ; Lange, Julie R ; Pockaj, B. A. ; Rosenberg, S. A. / Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers : A pilot study. In: Journal of Urology. 1992 ; Vol. 147, No. 1. pp. 24-30.
@article{f8705f241e274f6b893ea796a100e451,
title = "Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study",
abstract = "A total of 12 patients with stage 4 renal cell carcinoma and primary renal tumors in situ was entered into a pilot study using treatment with interleukin-2 and α-interferon followed by radical nephrectomy. Of the patients 11 underwent nephrectomy after an initial course of immunotherapy. Ten patients were able to receive a second course of immunotherapy given after nephrectomy. One patient achieved a complete response of lung and mediastinal metastases without any change in the primary renal tumor but after nephrectomy the patient remained in complete remission for greater than 11 months. A total of 3 patients achieved a partial response at some extrarenal sites but they had progression elsewhere. Toxicity was similar to previous experience with this immunotherapy regimen. Therefore, we demonstrated that metastatic tumor regression is possible with primary renal tumors in situ and that aggressive interleukin-2-based immunotherapy can be tolerated in the presence of a large renal tumor.",
keywords = "carcinoma, renal cell, immunotherapy, interferon type I, interleukin-2, kidney neoplasms",
author = "Spencer, {W. F.} and Linehan, {W. M.} and Walther, {M. M.} and Haas, {G. P.} and Lotze, {M. T.} and Suzanne Topalian and Yang, {J. C.} and Merino, {M. J.} and Lange, {Julie R} and Pockaj, {B. A.} and Rosenberg, {S. A.}",
year = "1992",
language = "English (US)",
volume = "147",
pages = "24--30",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers

T2 - A pilot study

AU - Spencer, W. F.

AU - Linehan, W. M.

AU - Walther, M. M.

AU - Haas, G. P.

AU - Lotze, M. T.

AU - Topalian, Suzanne

AU - Yang, J. C.

AU - Merino, M. J.

AU - Lange, Julie R

AU - Pockaj, B. A.

AU - Rosenberg, S. A.

PY - 1992

Y1 - 1992

N2 - A total of 12 patients with stage 4 renal cell carcinoma and primary renal tumors in situ was entered into a pilot study using treatment with interleukin-2 and α-interferon followed by radical nephrectomy. Of the patients 11 underwent nephrectomy after an initial course of immunotherapy. Ten patients were able to receive a second course of immunotherapy given after nephrectomy. One patient achieved a complete response of lung and mediastinal metastases without any change in the primary renal tumor but after nephrectomy the patient remained in complete remission for greater than 11 months. A total of 3 patients achieved a partial response at some extrarenal sites but they had progression elsewhere. Toxicity was similar to previous experience with this immunotherapy regimen. Therefore, we demonstrated that metastatic tumor regression is possible with primary renal tumors in situ and that aggressive interleukin-2-based immunotherapy can be tolerated in the presence of a large renal tumor.

AB - A total of 12 patients with stage 4 renal cell carcinoma and primary renal tumors in situ was entered into a pilot study using treatment with interleukin-2 and α-interferon followed by radical nephrectomy. Of the patients 11 underwent nephrectomy after an initial course of immunotherapy. Ten patients were able to receive a second course of immunotherapy given after nephrectomy. One patient achieved a complete response of lung and mediastinal metastases without any change in the primary renal tumor but after nephrectomy the patient remained in complete remission for greater than 11 months. A total of 3 patients achieved a partial response at some extrarenal sites but they had progression elsewhere. Toxicity was similar to previous experience with this immunotherapy regimen. Therefore, we demonstrated that metastatic tumor regression is possible with primary renal tumors in situ and that aggressive interleukin-2-based immunotherapy can be tolerated in the presence of a large renal tumor.

KW - carcinoma, renal cell

KW - immunotherapy

KW - interferon type I

KW - interleukin-2

KW - kidney neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0026575190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026575190&partnerID=8YFLogxK

M3 - Article

C2 - 1729540

AN - SCOPUS:0026575190

VL - 147

SP - 24

EP - 30

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -